Natural Capsules Ltd. (BSE: 524654) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹162 Cr, it ranks #2,823 by market cap among the 6,197 Indian listed companies on FinBizNet, and #40 of 63 in Pharmaceuticals. At ₹155.00 (as of 16 Nov 2026), the share price is 33.8% below its 52-week high of ₹234.00 and 18.2% above its 52-week low of ₹131.16. The share price is down 25.5% over one year and up 3.5% over three months.
| Current Price | ₹155.00 |
|---|---|
| Market Cap | ₹162 Cr |
| BSE Code | 524654 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -10.03% |
| Return on Assets | -3.02% |
| 52-Week Range | ₹131.16 – ₹234.00 |
| 1-Year Price Change | -25.5% |
| 3-Month Price Change | +3.5% |
| Beta (1Y) | 0.76 |
| Dividend Yield | 0.00% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.naturalcapsules.com |
| Revenue | ₹51 Cr |
|---|---|
| Net Profit | ₹-4 Cr |
| Net Margin | -8.3% |
| EPS (Basic) | ₹-4.08 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Natural Capsules Ltd. reported revenue of ₹51 Cr in Q2 FY27, up 11.7% from ₹46 Cr in Q2 FY26 and up 5.0% from ₹49 Cr in Q1 FY27. It posted a net loss of ₹4 Cr for the quarter, against a net loss of ₹7 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹38 Cr (Q3 FY26) to ₹58 Cr (Q4 FY26). The company reported a net loss in 6 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹51 Cr | −₹4 Cr | −8.3% |
| Q1 FY27 | ₹49 Cr | −₹6 Cr | −11.8% |
| Q4 FY26 | ₹58 Cr | −₹5 Cr | −8.5% |
| Q3 FY26 | ₹38 Cr | −₹7 Cr | −18.9% |
| Q2 FY26 | ₹46 Cr | −₹7 Cr | −15.3% |
| Q1 FY26 | ₹45 Cr | −₹6 Cr | −12.3% |
| Q4 FY25 | ₹45 Cr | ₹1 Cr | 1.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.92% of Natural Capsules Ltd.'s shares as of Sept 2026, against 51.26% in Sept 2025 (−0.34 percentage points). Delivery averaged 79.5% of traded volume across 8 NSE sessions (3 Nov 2026 – 13 Nov 2026).
Natural Capsules Limited engages in manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy free gelatin, shiny gelatin, sodium lauryl sulfate free gelatin, halal certified gelatin, fast release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.
1. Manufacture of Capsules-This segment manufactures hard capsules for pharmaceutical and dietary supplement industries. 2. Capsules-This segment manufactures hard gelatin capsule shells, hard cellulose capsule shells, and pharmaceutical dosage forms in capsule dosage form. 3. Segment Adjustment-0 4. Formulation-This segment is involved in formulating the pharmaceutical dosage forms in capsule dosage form, both pharma and neutraceutical products.
1. Capsules-92.8% 2. API-7.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Natural Capsules Ltd. | ₹162 Cr | n/m | -10.03% | ₹51 Cr | -25.5% |
Listed by market capitalisation. Ratios are shown for context only.
Natural Capsules Ltd. is trading at ₹155.00, with a market capitalisation of ₹162 Cr.
Natural Capsules Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Natural Capsules Ltd. has a return on equity of -10.03%.
Natural Capsules Ltd. is listed on the BSE under the scrip code 524654.
Natural Capsules Ltd.'s share price is down 25.5% over one year and up 3.5% over three months. Its 52-week range is ₹131.16 to ₹234.00.
In Q2 FY27, Natural Capsules Ltd. reported revenue of ₹51 Cr and net profit of ₹-4 Cr, with basic EPS of ₹-4.08 (consolidated, parsed from the company's exchange filing).
Natural Capsules Ltd. reported revenue of ₹51 Cr in Q2 FY27, up 11.7% from ₹46 Cr in Q2 FY26 and up 5.0% from ₹49 Cr in Q1 FY27.
Promoters held 50.92% of Natural Capsules Ltd.'s shares as of Sept 2026, against 51.26% in Sept 2025 (−0.34 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.